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In the present investigation, a series of novel (Z)-5-((5-chloro-1H-indol-3-yl)methylene)thiazolidine-2,4-dione analogues 
have been designed and synthesized in good yields with the objective of selective N-alkylation at thiazolidine 2,4-dione ring 
in competence with indole ring under basic conditions in the presence of aprotic solvent dimethylformamide (DMF). The 
newly synthesized compounds have been characterized by spectral data (IR, 1H and 13C NMR, NOE, NOESY, 1H-1H-COSY 
and LC-MS). Further, molecular docking and ADME studies have revealed that the newly synthesized compounds have 
very good docking score against antidiabetic and anti-inflammation activities (PPARy and COX-2) as compared with 
standard rosiglitazone. 
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Diabetics and inflammation together plays an important 
role in the pathogenesis of obesity-related insulin 
resistance, impaired insulin secretion, and diabetes-
related vascular complications1.Type 2 diabetes mellitus 
(T2DM) is a metabolic disorder characterized by insulin 
resistance and hyperglycemia. T2DM is associated 
with chronic low-grade inflammation. During the 
hyperglycemia condition elevated free fatty acids 
synthesis may promote inflammation, with aid of 
glucose consumption along with alterations in oxidative 
phosphorylation. Patient suffering from T2DM, the  
islets display features of an inflammatory process by 
enhancing the pro-inflammatory cytokinesand various 
chemokines and macrophage activation2. The mRNA of 
COX-2 levels along with IL-1β have upregulated by 
maintenance of human islets during hyperglycemic 
condition3. However, there is currently a lack of 
effective drugs for preventing the development of 
hyperglycaemic condition in diabetic patients. 
Thiazolidinediones (also called glitazones) are a class of 
medicines that have been used for the treatment of type 
2 diabetes. Substituted 3-alkyl indole moieties are of 
much importance as they are widely distributed in nature 
and reveal a broadrange of biological activity4.Indoles 
with a substituent at the 3-position are considered as a 
venerable pharmacophore in drug discovery as well as 
found in various range of natural products5. 5-Indolyl-
thiazolidine-2,4-dione derivatives have been emphasized 
in the field of synthetic organic chemistry6–8. The 
literature data indicated that 2,4-thiazolidinone moiety 
attached to the indole ring, which may prone to be 
potential antihyperglycemic9,10 and anti-cancer11,12 
agents. Despite, number of methodologies reported for 
the synthesis N-alkylated indolyl thiazolidine 2,4-dione 
derivatives, the results obtained were either a 
disubstituted N-alkylated compounds13or some of the 
examples have shown that initially NH proton of the 
either thiazolidine 2,4-dione ring14 or indole moiety were 
protected separately and then taken for Knoevenagel 
condensation reaction6,11,13,15. Therefore, it is essential to 
pay more attention for the development of new method 
towards synthesis of selectivemono substituted 
N-alkylation at thiazolidine 2,4-dione ring (N3). Based 
on that, we reported a newsyntheticmethod for selective 
N-alkylation of (Z)-5-((5-chloro-1H-indol-3-yl)methylene) 
thiazol-idine-2,4-dione, analogues starting from 5-
chloro-1H-indole-3-carboxaldehyde (1). The newly 
synthesizedcompounds were further investigated for 
molecular docking and ADME studies. 
Results and Discussion 
Chemistry 
The synthetic route is disclosed in the Scheme I, 5-
chloro-indole-3-carboxaldehyde (1) and thiazolidine-
2,4-dione(2) in toluene using piperidine as base via 
Knoevenagel condensation led to the desired (Z)-5-((5-





dione(3). Compound 3 was subjected for selective N-
alkylation at thiazolidine 2,4-dione ring (N3) and 
obtained the compound 4(a-g). To obtain the optimized 
reaction conditions for the synthesis of compound 4a, 
the study was initiated with the reactions on compound 3 
by varying the base molar equivalents of potassium 
carbonate in presence of different solvents. Conducted 
experiment in aprotic solvent DMF, the high selective 
N-alkylation was observed at N3 position of thiazolidine 
2,4-dione ring. Further, the temperature optimum 
reaction was performed for the preparation of compound 
4a. The reaction proceeded smoothly, and most 
complete conversion of reactants was observed at 100oC, 
with minimum formation of dialkylated compound(5). 
The results obtained are summarized in Table I. The 
higher temperature caused a decrease in yield and 
formation dialkylated compounds were noticed. With 
the optimized reaction conditions in hand, we further 
investigated the scope and functional group potential of 
our present protocol with various substituted alkylating 
reagents, aliphatic/ substituted benzyl and heteroaryl 
compounds. The reactions involving aliphatic / aryl 
halides, observed formation of major mono substituted 
compound 4a. In case of heterocyclic halides compound 
4b, isolated both mono and dialkylated compounds as 
(4b) and (5b). The challenge was to separate both mono 
and di N-alkylated compounds as TLC showed very 
close RF values. The crude compounds were subjected 
for purification on instrument Biotage−Isolera one flash 
purification system and separate both mono and 
disubstituted compounds. The compounds eluted with a 
mixture of solvents from 5% to 20% ethyl acetate in 
petroleum ether. The Compounds 4b and 4g were 
further subjected for purification by preparative HPLC 
(Reverse phase method, using mobile phase 0.1% 
trifluoroacetic acid in acetonitrile: water and column 
used was C18 column) to get pure mono substituted 
compounds. The yields of all newly synthesized 
compounds (4a-g) are in the ratio from 20 to 45%.  
 
Mechanistic rationalization for the formation of 
compound 4 (Scheme II) 
Selective alkylated product (4) from the indole 
derivative (3) : Initially the alkylating reagent reacted 
with base K2CO3, to generate the reactive species,  
R-CH2⊕ and KCO3⊖where KCO3⊖ abstracts NH 
proton of thiazolidine-2,4-dione derivative (3) results 
the formation of imine ion intermediate (I).Then the 
imine ion stabilises through its more stabilised enolic 
form II (because of extended conjugates). Finally the 
stabilised ion II react with the carbocation species 
R-CH2⊕generated in situ, to form the selective N-
alkylated product 4. 
 
2D-NMR Studies on compounds 4a and 4b 
The present work was focussed on to ascertain 
whether the N-alkylation reaction step is at indole 
nucleus (N1) or at thiazolidine 2,4-dione nucleus (N3). 
The structures were confirmed by 2D NMR data 
 
 
Scheme I — Selective N-alkylation of (Z)-5-((5-chloro-1H-indol-3-yl)methylene) thiazolidine-2,4-dione (3). 
 
Table I — Base and temperature optimization for the synthesis of 4a a 










1 Toluene 1 1 110 24 − 
2 Acetone 1 1 55 16 − 
3 DMF 1 − 125 − − 
4 DMF 1 1 125 5 − 
5 DMF 1 3 125 3 − 
6 DMF 1 3 100 3 42 b 
a Reaction conditions: 3 (1.0mmol), RCH2X (4-CF3-PhCH2Br) (1.0 mmol), K2CO3 (3.0mmol) and DMF (10mL). 
b Isolated yield of the product. 
 




(NOESY/NOE and 1H-1H COSY data). Two examples 
were considered for this study compound 4a and 
compound 4b.  
The 1H NMR analysis depicted that, characteristic 
singlet (N1-H) present in the indole ring showed a 
chemical shift variation between δ12.06 and 
δ12.35ppm. The N-substitution at thiazolidine 2,4-
dione nucleus (N3-H), it was observed in spectra,  
the characteristic signals of aromatic protons with 
chemical shift around δ7.25, δ7.90, δ8.26 and 
aliphatic N3-CH2 proton at δ4.94 ppm. To confirm 
whether the N-alkylation took place at the indole 
nucleus (N1-H) or at thiazolidine 2,4-dione –(N3-H), a 
detailed study by 2D NMR data was performed on 
compound 4a.The NOESY spectrum has shown in 
Figure 1 for the compound 4a, it revealed that 
correlation between NH group at δ12.35 ppm of the 
indole ring and neighbour hydrogen -CH- group (C2’-
H), δ7.78 ppm, the interaction of N-CH2 at δ4.94 ppm 
with para pattern of aromatic doublet at δ7.52 ppm 
(Figure 1) has shown N-alkylation happened at ring 
N3-H of thiazolidine 2,4-dione ring. 
The above compound was also characterized by 1D-
NOE study and irradiated the N-CH2 proton at δ4.94 
ppm; it was observed that there is an enhancement at 
doublet aromatic phenyl ring at δ7.56 ppm, which 
demonstrates N-alkylation has taken place at 
thiazolidine 2,4-dione ring (N3-H), as we have not 
observed any interaction at the indole nucleus (Figure 2). 
Spectrum of the compound 4a was observed 
correlation between hydrogen NH group (δ12.35ppm) 
of the indole ring and the neighbour hydrogen -CH 
group at δ7.78ppm (C2’-H). With this result, it was 
clear that there is no selective substitution at NH 
proton of indole ring (N1-H) (Figure 3). 
In compound4b, the correlation between NH group 
at δ12.34ppm of the indole ring and neighbour 
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bond with Ser530, Arg120, and π-π stacking with 
Trp387 with a docking score of -10.35 kcal/mol 
(Table II). 
In case of COX-2, ligand 4a interacted very well 
via π-cation interaction with Arg120 and hydrogen 
bond with Tyr355 with a docking score of -9.40 
kcal/mol. The standard rosiglitazone interacted with 
COX-2 via hydrogen bonding with Ser530, Tyr355 
and form salt bridge with Glu524. The insulin 
sensitivity towards its target is achieved by two ways 
by systemic insulin sensitization or by direct 
interaction with peroxisome proliferator-activated 
receptor (PPAR-γ) on the transcription of genes like 
GLUT2 and β-glucokinase which help in reducing the 
blood glucose level18. The A-chain and B-chain of 
PPAR-γ efficiently interacted with ligand 4c, via π-π 
stacking with Tyr327 of both the chains; apart from 
this, the ligand also interacted with His449 with the 
same interaction and hydrogen bond with catalytical 
water molecule at B-chain. These results suggest that 
ligands 4a and 4c would be better inhibitors for COX-
2 and PPAR-γ, respectively. Based on the molecular 
docking studies, the docking score for PPAR-γ regarding 
4a is slightly lower comparatively (Table II). 
Further in vitro or in vivo assay will warranty the 
pharmacological activity against diabetic with an 
inflammatory condition.  
ADME studies reveal that the newly synthesized 
ligands have good ADME properties as compared 
with the data from 95% of drug which are already 





The starting materials were purchased commercially 
and used without purification. Melting points were 
recorded on instrument BUCHI-Melting point M-65, 
Thin layer chromatography was performed on  
Silica gel G, IR spectra were recorded on FT-IR-
Perkin Elmer: Spectrum.NMR recorded on Bruker 
instrument (400MHz), LCMS performed on Agilent 
Infinity Lab LC/MSD. Microanalyses were performed 
using Vario EL III model CHNS analyser (Vario 
Germany). Purification was performed on instrument 
BiotageIsolera one Flash purification. 
 
Preparation of 3 from 1 and 2: (Z)-5-((5-chloro-
1H-indol-3-yl)methylene) thiazolidine-2,4-dione 
A mixture of 1 (1g 5.5 mmol), 2 (0.65g 5.5 mmol) 
and piperidine (1.5 mL) was refluxed in toluene  
(50 mL) for 3h. Yellow colour solid precipitated from 
the reaction mixture. Completion of the reaction was 
monitored by TLC. After completion of the reaction, 








the precipitated solid was filtered, washed with 
petroleum ether, and dried to obtain compound 3. 
3: Yellow solid, Yield: 0.7g (48%), melting range: 
250 to 264 oC, FT- IR [KBr in cm-1] υmax: 3424(-NH), 
2930(C-H), 1783, 1670 (both -C=O), 1322 (C-N), 
1588 (C=C), 651.73 (C-S),1H -NMR (400 MHz, 
DMSO-d6) (ppm) δH:12.33 (br, s, 1H, N3-H), 12.24 
(br, s, 1H, N1-H), 8.05 (S, 1H, C1”-H), 8.02(d, 1H, 
C4’-H, J=1.6Hz), 7.79-7.79 (d, 1H, C2’’-H, J= 1,2Hz), 
7.52-7.50(d,1H,C7’-1H, J=8.4Hz),7.26-7.23(dd, 1H, 
C6’-H, J=2Hz), LC-MS (C12H7ClN2O2S): calculated 
m/z: 278.71: Found: m/z : 279 (M+1). 
 
General procedure for the synthesis of compounds 
4a-g 
An equimolar mixture of (Z)-5-((5-chloro-1H-indol-
3-yl)methylene)thiazolidine-2,4-dione (3, 0.54mmol), 
alkylating reagent (0.54mmol), potassium carbonate 
(3 mmol), and anhydrous DMF (10 mL) was 
combined and heated at100oC for 3 h. The completion 
of the reaction was monitored by TLC. After 
completion of reaction, cooled to room temperature, 
filtered on celite bed, collected filtrate and 
concentrated the solvent under rota vacuum at 50oC. 
Residue obtained was diluted with ethyl acetate and 
the organic layer was washed with water, brine 
solution, and dried over anhydrous sodium sulphate, 
filtered and concentrated. Residue obtained was 
purified by column chromatography over silica gel 
(Silica gel 230-400 mesh) using petroleum ether: 
ethyl acetate (80:20) mixture as eluant to afford the 
product, (Z)-5-((5-chloro-1H-indol-3-yl)methylene)- 
3(aliphatic/aromatic/heterocyclic)thiazolidine-2,4-
dione4(a-g). In case of compounds 4b and 5b obtained 
was separated and characterized. 
 
(Z)-5-((5-Chloro-1H-indol-3-yl) methylene)-3-(4-
(trifluoromethyl) benzyl) thiazolidine-2,4-dione, 4a 
Yellow solid, Yield: 42.7%, melting range (257-
264°C), FT- IR [KBr in cm-1] Vmax: 3424(-NH), 
2930(C-H vinylic), 1676, 1604.2(-C=O), 1323.66(C-
N), 1456.76(C=C), 598.10(C-S).1H -NMR (400 MHz, 
DMSO-d6) (ppm) δH: 12.35 (br, s, 1H, N1-H), 8.26 (s, 
1H, C1-H), 8.08 (d, 1H, C4’ -H, Jm=2Hz), 7.90-7.89 (d, 
1H, C2’-H, Jm=2.8Hz), 7.75-7.73 (dd, 2H, C3’’ -H, C5’’ 
-H, Jo=8.4Hz), 7.56-7.52(m, 3H, C2’’ – H, C6’’ -H, C7’ 
–H), 7.28-7.25 (dd, 1H, C6’ -H, Jm= 2Hz), 4.98 (s, 2H, 
N3-H of TZD). 
13C-NMR (100MHz, DMSO-d6) 
(ppm) δC: 167.55 and 165.722 (C=O), 140.9, 135.2, 
130.9, 128.73, 128.51, 126.65,126.43, 126.043,123.7, 
118.71, 114.66, 114.49, 110.72, 40.5, LC-MS 
(C20H12ClF3N2O2S) calculated m/z : 436.83, Found: 
M+2: 438.9, Anal. Calcd for C20H12ClF3N2O2S : C, 
54.99; H, 2.77; N, 6.41; S, 7.34; Found: C, 54.97; H, 
2.93, N, 6.55, S, 7.28%. 
 
(Z)-5-((5-Chloro-1H-indol-3-yl)methylene)-3-
(pyridine-2-ylmethyl) thiazolidine-2,4-dione, 4b 
Yellow solid,Yield: 30.3%, melting range: 244.2-
257.5°C, FT- IR [KBr in cm-1] Vmax: 3124(-NH), 2924 
(C-H vinylic), 1667 and 1597 (-C=O), 1324 (C-N), 
1481 (C=C), 537 (C-S). 1H -NMR (400 MHz, DMSO-
d6) (ppm) δH: 12.34 (br, s, 1H, N1-H), 8.49-8.47 (dd, 
1H, C6’’, Jo=7.2Hz), 8.24(s, 1H, C1-H), 8.08-8.07 (d, 
1H, C3’’-H, J=1.6Hz), 7.91-7.90 (d, 1H, C2’-H, 
Jm=2.4Hz), 7.82 (t, 1H, C6’’-H, Jo =6Hz), 7.54-7.52 
(dd, 1H, C5’’-H Jo = 8.4Hz) 7.42-7.40 (dd, 1H, C4’’-H 
Jo =8Hz) 7.32-7.30 (t, 1H, C7’Jo =4.8Hz) 7.29-7.25 
(dd, 1H, C4’-H, Jm-2Hz), 4.988(s 2H, N3-H of 
TZD),13C-NMR (100MHz, DMSO-d6) (ppm) δC: 
167.49 and 165.80 (C=O), 154.72, 149.62, 137.42, 
135.20, 130.77, 128.54, 126.38, 126.23, 123.16, 121, 
118.73, 115.04, 114.47, 110.76 and 45.94, LC-MS 
(C18H12ClN3O2S) calculated m/z: 368.82 and Found 
M+2: 372, Anal. Calcd C18H12ClN3O2S : C, 58.46; H, 
3.27; N, 11.36; S, 8.67; Found C, 57.85, H, 3.32, N, 





Yellow solid,Yield: 50mg, melting range: 218-
223°C, FT- IR [KBr in cm-1] Vmax: 3122 (C-H 
Vinylic), 1672 and 1589 (-C=O), 1521 (C=C),  
1361 (C-N), 545 (C-S),1H -NMR (400 MHz, DMSO-
d6) (ppm) δH: 8.52-8.42(dd, 2H, C6’-H, C6’’’-H, 
J=8.4Hz and J=0.8Hz), 8.24 (s, 1H, C1’’H vinylic), 
8.15(s, 1H, C2’-H), 8.13-8.12 (d, 1H, C3’-H, Jm=2Hz), 
7.80 (q, 2H, C5’’-H, C5’’’-H, Jm = 3.2Hz),  
7.57-7.55(dd, 1H, C7’-H, Jo =8.8Hz) 7.43-7.41 (dd, 
1H, C6’-H, Jo =8Hz), 7.32-7.25 (m, 4H, C4’-H, C4’’-H, 
C4’’’-H, C3’’-H), 5.72 (s, 2H, N1-H of indole), 4.99  
(s, 2H, N3-H of TZD),
13C-NMR (100MHz, DMSO-
d6) (ppm) δC:167.43 and 165.78 (C=O), 156.33, 
154.69, 149.99, 149.63, 137.77, 137.43, 135.28, 
134.09, 129.19, 126.90, 125.62, 123.83, 123.48, 
123.17, 122.12, 121.95, 119.08, 115.49, 113.43, 
110.33, 52.15, 45.96, LC-MS (C24H17ClN4O2S): 
calculated m/z 460.94 and Found M+2 : 463.1, Anal. 
Calcd C24H17ClN4O2S: C,62.54; H,3.72; N, 12.16; 
S,6.96; Found: C, 63.04; H,3.552, N,12.19, S, 
6.784%. 





methylbenzyl) thiazolidine-2,4-dione, 4c 
Yellow solid,Yield: 20.5%, melting range: 260-
277°C, FT- IR [KBr in cm-1] Vmax: 3279 (br, indole-
NH), 2924 (C-H vinylic), 1667, 1605 (C=O),1H -
NMR (400 MHz, DMSO-d6) (ppm) δH: 12.35 (br, s, 
1H, N1-H, of Indole), 8.26 (s, 1H, C1”-H Vinylic) 8.09 
(d,1H, C2’-H, Jm=2Hz), 7.91-7.90(d, 1H, C6’-H, 
Jm=2.8Hz), 7.28-7.25 (dd, 1H, C5’’-H, Jo =10.8Hz), 
7.23-7.16 (m, 3H, C6’’, C3’’, C4’-H), 7.05-7.04 (dd, 1H, 
C4’’-H, JO=6.8Hz); LC-MS (C20H15ClN2O2S): 
calculated m/z: 382.86 and Found: M+2: 385. 
 
(Z)-4-((5-((5-Chloro-1H-indol-3-yl)methylene)-2,4-
dioxothiazolidin-3-yl) methyl)benzonitrile, 4d 
Yellow solid,Yield: 19%, melting range: 250-
265°C, FT- IR [KBr in cm-1] Vmax: 3295 (br, Indole-
NH), 3123 (aromatic CH), 2931(C-H vinylic), 2231 
(CN -Nitrile),1669, 1602 (-C=O), 1375 (C-N), 1H -
NMR (400 MHz, DMSO-d6) (ppm) δH: 12.38(br, s, 
1H, N1-H, of Indole) 8.26(s 1H, C1”-H, Vinylic) 8.08 
(d,1H, C2’-H, Jm=2Hz), 7.90-7.89(d, 1H, C6’-H, 
Jm=2.8Hz), 7.85-7.83 (dd, 2H, C6’’-H, C2’’-H, Jm=2Hz, 
Jm=1.6Hz) 7.54-7.50 (m, 3H, C7’-H, C3’’-H, C4’’-H), 
7.28-7.27(dd, 1H, C6’, Jm= 2Hz), 4.93 (s, 2H, N3-H of 
TZD), LC-MS (C20H12ClN3O2S), : calculated m/z 
393.85, Found: M-2: 392. 
 
(Z)-5-((5-Chloro-1H-indol-3-yl) methylene)-3-(3-
nitrobenzyl) thiazolidine-2,4-dione, 4e 
Yellow solid, Yield: 45.5%,melting range: 219.5-
241.5°C, FT- IR [KBr in cm-1] Vmax: 3300(br,Indole-
NH),3097.39(aromaticCH),2933.93(C-
H,vinylic),1669,1600(C=O),1570.73 (N-O), 1H -NMR 
(400 MHz, DMSO-d6) (ppm) δH: 12.359 (br, s, 1H, 
N1-H of Indole), 8.277(s, 1H, C1’’-H, Vinylic), 8.206-
8.164 (dd, 2H, C2’’-H, C6’’-H, J=1.6Hz), 8.09-8.09(d, 
1H, C2’-H, J=1.6Hz), 7.90-7.89(d,1H, C6’-H, 
Jm=2.8Hz), 7.80-7.79 (dd, 1H, C4’’-H, Jo =7.2Hz), 
7.70-7.66 (t, 1H, C5’’-H, J=8.4Hz) 7.53-7.50 (dd, 1H, 
C2’’-H, Jm=2Hz, 3.2Hz), 7.27-7.26 (dd, 1H, C7’-H, 
Jm=2Hz, 3.2Hz), 4.99 (s, 2H, N3-H of TZD), LC-MS 
(C19H12ClN3O4S) : calculated m/z: 413.83 and Found 




Yellow solid,Yield: 24.4 %, melting range: 217.7-
225.7°C, FT- IR [KBr in cm-1] Vmax: 3205.58 (br, 
Indole-NH), 2937.72 (C-H vinylic), 1727.44, 1651.29 
(C=O),1H -NMR (400 MHz, DMSO-d6) (ppm) δH: 
12.31 (s, 1H, N1-H of Indole), 8.21 (s, 1H, C1’’-H, 
Vinylic), 8.07(d, 1H, C2’-H, Jm=1.2Hz), 7.86(s,1H, 
C74’-H), 7.53-7.51(dd,1H, C7’-H, Jo=8.8Hz), 7.27-
7.25(dd,1H, C6’-H, Jm=1.6Hz), 3.72-3.66(q, 2H, C2’’-
H, J=7.2Hz),1.19-1.15(t, 3H, C3’’-H, J=7.2Hz), LC-




(cyclopropylmethyl) thizolidine-2,4-dione, 4g 
Yellow solid,Yield: 22.5 %, melting range: 181.5-
195.9°C, FT- IR [KBr in cm-1] Vmax: 3097.5 (br, 
Indole-NH), 2933.97 (C-H vinylic), 1730.04 (C=O), 
1668.7(C=O),1H -NMR (400 MHz, DMSO-d6) (ppm) 
δH: 12.329(br, s, 1H, N1-H of Indole), 8.23 (s, 1H, C1” 
-H,) 8.08 (d, 1H, C2’-H, Jm=2Hz), 7.87(d, 1H, C7’-H, 
J=2.8Hz), 7.54-7.51 (dd, 1H, C6’-H, Jo =8.8Hz), 7.25-
7.25(dd, 1H, C4’-H, Jm=2Hz), 3.55-3.53 (d, 2H, N3-H 
of TZD C2”-H, Jo =7.2Hz), 1.16-1.12(q, 1H, C3”-H, 
J=4.8Hz), 0.52-0.47 (q, 2H, C4”-H, J=4.4Hz), 0.36-
0.32 (q, 2H, C5”-H, J=4Hz), LC-MS (C16H13 
ClN2O2S): calculated m/z: 332.80, Found: M-2: 331. 
 
Conclusions 
Understanding and controlling indole-thiazolidine 
2,4-dione N-alkylation site selectivity is critical to 
many medicinal chemistry programs.This study has 
demonstrated that the N-alkylationon (Z)-5-((5-chloro-
1H-indol-3-yl)methylene)thiazolidine-2,4-dioneresulted 
alkylated at N3 position of thiazolidine-2,4-dione 
ring.Interestingly, we have notobserved alkylation 
reaction towards indole-NH ring(N1).This was further 
confirmed by performing 2D NMR studies on the 
isolated compounds.The molecular docking studies 
revealed that compounds 4a, 4b, 4c and 4d, would be 
better inhibitors for COX-2 and PPAR-γ, respectively. 
The above results indicated that the(Z)-5-((5-chloro-
1H-indol-3-yl)methylene)thiazolidine-2,4-dionederivatives 
may enhance the efficacy towards the antidiabetic and 
anti-inflammatory activities. Further in vitro or in vivo 
assay will warranty the pharmacological activity 
against diabetic with an inflammatory condition. 
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